Clinical trials: Huntington's Disease
Huntington's Disease, Chorea
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
- Trial name
- NCT01019473
- Testing
- AFQ056
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease, Tourette Syndrome
Brain Stimulation in Movement Disorders
Brain stimulation in movement disorders This trial will explore the effects of very gentle electrical stimulation of the brain in patients with movement disorders.
- Trial name
- NCT02216474
- Testing
- Transcranial direct current stimulation
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Birmingham and Solihull Mental Health NHS Foundation Trust
Huntington Disease
FuRST 2.0 Cognitive Pre-testing - Round 2
The study is a single, cross-sectional cognitive interview of FuRST 2.0, functional rating scale, administered to forty Huntington's Disease Gene Expansion Carriers (HDGECs) and potentially, their companions (the companion's…
- Trial name
- NCT03709173
- Testing
- FuRST 2.0
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM)
The study was conducted at the University Isabel I, Burgos in collaboration with the Hospital Universitario Burgos, Spain, through the creation of a multidisciplinary research team including graduates in physical activity and…
- Trial name
- BEHD-EM (NCT05250323)
- Testing
- observational tests in face-to-face visit
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario de Burgos
Huntington's Disease
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in…
- Trial name
- PRECISION-HD2 (NCT03225846)
- Testing
- WVE-120102
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 88 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington Disease
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
Cellavita-HD is a stem-cell therapy for Huntington's Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington's disease patients…
- Trial name
- ADORE-EXT (NCT04219241)
- Testing
- Cellavita-HD
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Azidus Brasil
Huntington Disease
A Pilot Study of Nutritional Status in Patients With Huntington's Disease
It is known that weight loss is a poor prognostic marker in HD, but it is not known which dietary interventions are optimal at different stages of the disease.
- Trial name
- NCT05668520
- Testing
- Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Aberdeen
Huntington Disease
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
- Trial name
- NCT06254482
- Testing
- Votoplam
- Where
- 24 sites in Australia, Austria and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in…
- Trial name
- NCT03434548
- Testing
- PET imaging, Multi-modal MRI imaging
- Where
- United Kingdom
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- King's College London
Huntington Disease
Creatine Safety and Tolerability in Premanifest HD: PRECREST
PRECREST is a two phase protocol for Huntington's disease in which 60 premanifest and at-risk subjects will first be randomized into a double blind placebo controlled dose titration study bringing them to 30 grams daily or their…
- Trial name
- PRECREST (NCT00592995)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease
Efficacy and Safety of NestaCell® in Huntington's Disease
Huntington's disease (HD) is a rare neurodegenerative condition caused by increased CAG trinucleotide repeats in the HTT gene, on chromosome 4. The estimated global prevalence is 2.71 cases per 100,000 inhabitants.
- Trial name
- STAR (NCT06097780)
- Testing
- NestaCell®
- Volunteers
- 120 people
- Sponsor
- Azidus Brasil
Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
- Trial name
- NCT07536061
- Testing
- SRP-1005
- Where
- 5 sites in Australia, New Zealand and 2 more
- Volunteers
- 32 people
- Sponsor
- Sarepta Therapeutics, Inc.
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617847
- Testing
- WVE-120101
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 27 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington's Disease
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659.
- Trial name
- LONGPDE10 (NCT02956148)
- Testing
- Radioligand [18F]MNI-659
- Where
- 7 sites in Denmark, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia.
- Trial name
- OPEN-HART (NCT01306929)
- Testing
- pridopidine
- Volunteers
- 134 people
- Sponsor
- Prilenia
Huntington Disease
31P-MRS and Huntington Disease
The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.
- Trial name
- PRO-MH (NCT01359774)
- Testing
- 31P-MR spectroscopy, 31P-RMN spectroscopy
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington Disease
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.
- Trial name
- NCT05224115
- Testing
- [11C]CHDI-00485180-R, [11C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neurodegenerative Disease, Weight Loss
Electronic-health Application To Measure Outcomes REmotely Clinical Trial
This is a phase II feasibility, safety, tolerability and preliminary efficacy study of an e-Health application versus in-person nutritional counseling to maintain or increase weight in patients with neurodegenerative diseases…
- Conditions
- Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease
- Trial name
- EAT MORE (NCT02418546)
- Testing
- In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease, Juvenile
REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)
The study aims to monitor the progression of symptoms and signs of those affected by JHD using modified UHDRS scales of motor and function (functional assessment, TFC).
- Trial name
- JHD (NCT01590602)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 78 people
- Sponsor
- European Huntington's Disease Network